patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Prev Message Back To Forum Threaded View Next Message

bankerson

Rank: Treasurer [?]

Points: 22820 [?]

Votes: 138 Score: 2.9 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

News Today

posted on Oct 15, 2013 08:09AM

press release

Oct. 15, 2013, 3:00 a.m. EDT

Pluristem to Present Scientific Poster and Corporate Overview at Stem Cell Meeting on the Mesa

HAIFA, Israel, Oct 15, 2013 (GLOBE NEWSWIRE via COMTEX) -- Pluristem Therapeutics Inc. PSTI +0.29% (tase:PLTR), a leading developer of placenta-based cell therapies, announced today that the company will be actively participating in the Stem Cell Meeting on the Mesa on October 14-16, 2013.

William R. Prather RPh, MD, Pluristem's Senior Vice President of Corporate Development will deliver a corporate presentation on Pluristem on October 14 at 5 pm PT. Additionally, Dr. Prather will be presenting a scientific poster on October 16 titled, "PLacental eXpanded (PLX) Cell Treatment Ameliorates Toll-like Receptor-Mediated Preeclampsia in Mice".

The 2013 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the regenerative medicine industry with the scientific research community to advance stem cell science into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading scientists and researchers, in conjunction with the industry's premier annual Regen Med Partnering Forum. Combined, these meetings attract over 800 attendees from around the globe, fostering key partnerships through one-on-one meetings while also highlighting clinical and commercial progress in the field.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company's proprietary 3D micro-environmental technology and are an "off-the-shelf" product that requires no tissue matching prior to administration.

Pluristem has a strong intellectual property position, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team. For more information visit www.pluristem.com, the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6882